Taken together, these findings indicated that shorter overall survival and metastasis-free survival preferentially occurred in patients with MT-RNR1 709A in some subgroups, especially in HBV-related HCC, AST ≥ 31 IU/L, and histology grade 3-4 patients (see Figure 2 and Figure 4, bold p-values). This evidence concerns the gene NR4A2 and hepatocellular carcinoma.